JP2014527027A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014527027A5 JP2014527027A5 JP2014513706A JP2014513706A JP2014527027A5 JP 2014527027 A5 JP2014527027 A5 JP 2014527027A5 JP 2014513706 A JP2014513706 A JP 2014513706A JP 2014513706 A JP2014513706 A JP 2014513706A JP 2014527027 A5 JP2014527027 A5 JP 2014527027A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- alkyl
- ring
- atom
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 124
- 150000001875 compounds Chemical class 0.000 claims description 102
- 125000003545 alkoxy group Chemical group 0.000 claims description 70
- 125000003118 aryl group Chemical group 0.000 claims description 65
- 125000006413 ring segment Chemical group 0.000 claims description 65
- 125000001072 heteroaryl group Chemical group 0.000 claims description 64
- 125000000623 heterocyclic group Chemical group 0.000 claims description 62
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 59
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 50
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 46
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 41
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 38
- -1 hydroxy, methyl Chemical group 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 24
- 125000004043 oxo group Chemical group O=* 0.000 claims description 24
- OSDBJMYIUDLIRI-UHFFFAOYSA-N oxo-[[1-[[4-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxy]cyclohexyl]oxymethyl]pyridin-4-ylidene]methyl]azanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1COC1CCC(OCN2C=CC(=C[NH+]=O)C=C2)CC1 OSDBJMYIUDLIRI-UHFFFAOYSA-N 0.000 claims description 23
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
- 229910052736 halogen Inorganic materials 0.000 claims description 17
- 150000002367 halogens Chemical group 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- VHVGFEDTMPYCSX-UHFFFAOYSA-N [1-[[2,2-dimethyl-3-[[4-(oxoazaniumylmethylidene)pyridin-1-yl]methoxy]propoxy]methyl]pyridin-4-ylidene]methyl-oxoazanium;dichloride Chemical compound [Cl-].[Cl-].C1=CC(=C[NH+]=O)C=CN1COCC(C)(C)COCN1C=CC(=C[NH+]=O)C=C1 VHVGFEDTMPYCSX-UHFFFAOYSA-N 0.000 claims description 9
- 125000002619 bicyclic group Chemical group 0.000 claims description 9
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 9
- 230000004913 activation Effects 0.000 claims description 7
- 230000008484 agonism Effects 0.000 claims description 7
- 229910052739 hydrogen Inorganic materials 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims description 6
- 125000004980 cyclopropylene group Chemical group 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 5
- 230000002159 abnormal effect Effects 0.000 claims description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 206010064720 Lack of satiety Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 208000022531 anorexia Diseases 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 206010061428 decreased appetite Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 208000004104 gestational diabetes Diseases 0.000 claims description 2
- 208000030159 metabolic disease Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 125000001475 halogen functional group Chemical group 0.000 claims 16
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 9
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 claims 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 description 40
- 125000005843 halogen group Chemical group 0.000 description 34
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 32
- 229910052717 sulfur Inorganic materials 0.000 description 19
- 229910052760 oxygen Inorganic materials 0.000 description 14
- 125000001715 oxadiazolyl group Chemical group 0.000 description 10
- 125000002971 oxazolyl group Chemical group 0.000 description 10
- 125000003226 pyrazolyl group Chemical group 0.000 description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 description 9
- 125000001425 triazolyl group Chemical group 0.000 description 9
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 8
- 150000002148 esters Chemical class 0.000 description 8
- 229940002612 prodrug Drugs 0.000 description 8
- 239000000651 prodrug Substances 0.000 description 8
- 239000012453 solvate Substances 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 0 Cc(ccc(*)c1)c1OC Chemical compound Cc(ccc(*)c1)c1OC 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 description 4
- 235000010290 biphenyl Nutrition 0.000 description 4
- 239000004305 biphenyl Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical group O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 1
- INSZEJWMNPZYCP-SNAWJCMRSA-N CC(C)(N)[IH]/C=C/C Chemical compound CC(C)(N)[IH]/C=C/C INSZEJWMNPZYCP-SNAWJCMRSA-N 0.000 description 1
- MAIFURVUXIRYSZ-UHFFFAOYSA-N Cc(cc1)c(C(F)(F)F)cc1OC Chemical compound Cc(cc1)c(C(F)(F)F)cc1OC MAIFURVUXIRYSZ-UHFFFAOYSA-N 0.000 description 1
- FPGUYDZXCTUCOX-UHFFFAOYSA-N Cc(cc1)ccc1-c(cc1)ccc1-c1nc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3N(C)C)=O)=O)cc2)n[o]1 Chemical compound Cc(cc1)ccc1-c(cc1)ccc1-c1nc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)ccc3N(C)C)=O)=O)cc2)n[o]1 FPGUYDZXCTUCOX-UHFFFAOYSA-N 0.000 description 1
- TXXAVEHDCDMGNW-UHFFFAOYSA-N Cc(cc1)ccc1-c(cc1)ccc1-c1nc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc3cccc(CN)c3)=O)=O)cc2)n[o]1 Chemical compound Cc(cc1)ccc1-c(cc1)ccc1-c1nc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc3cccc(CN)c3)=O)=O)cc2)n[o]1 TXXAVEHDCDMGNW-UHFFFAOYSA-N 0.000 description 1
- KWYVKFLUXLNHSP-UHFFFAOYSA-N Cc(cc1)ccc1C#Cc1nc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)n[o]1 Chemical compound Cc(cc1)ccc1C#Cc1nc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)n[o]1 KWYVKFLUXLNHSP-UHFFFAOYSA-N 0.000 description 1
- BFUWWCJOMJNPLE-UHFFFAOYSA-N Cc(cc1)ccc1NC(c1nc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)n[o]1)=O Chemical compound Cc(cc1)ccc1NC(c1nc(-c2ccc(CN(CC(O)=O)C(c(cc3)ccc3NC(Cc(cc3)c(C(F)(F)F)cc3OC)=O)=O)cc2)n[o]1)=O BFUWWCJOMJNPLE-UHFFFAOYSA-N 0.000 description 1
- CHLICZRVGGXEOD-UHFFFAOYSA-N Cc(cc1)ccc1OC Chemical compound Cc(cc1)ccc1OC CHLICZRVGGXEOD-UHFFFAOYSA-N 0.000 description 1
- ZVHGCLSSXMTEBV-UHFFFAOYSA-N Cc1ccc(CCCc2nc(-c3ccc(CN(CC(O)=O)C(c(cc4)ccc4NC(Cc(cc4)c(C(F)(F)F)cc4OC)=O)=O)cc3)n[o]2)cc1 Chemical compound Cc1ccc(CCCc2nc(-c3ccc(CN(CC(O)=O)C(c(cc4)ccc4NC(Cc(cc4)c(C(F)(F)F)cc4OC)=O)=O)cc3)n[o]2)cc1 ZVHGCLSSXMTEBV-UHFFFAOYSA-N 0.000 description 1
- 108010011459 Exenatide Proteins 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 108010063919 Glucagon Receptors Proteins 0.000 description 1
- 102100040890 Glucagon receptor Human genes 0.000 description 1
- 102000015626 Glucagon-Like Peptide-2 Receptor Human genes 0.000 description 1
- 108010024044 Glucagon-Like Peptide-2 Receptor Proteins 0.000 description 1
- 101000684208 Homo sapiens Prolyl endopeptidase FAP Proteins 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- XVVOERDUTLJJHN-UHFFFAOYSA-N Lixisenatide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)NC(CC(N)=O)C(=O)NCC(=O)NCC(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1C(CCC1)C(=O)N1C(CCC1)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC(=O)C(NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCC(O)=O)NC(=O)C(CCSC)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC=1C=CC=CC=1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)CNC(=O)C(N)CC=1NC=NC=1)C(C)O)C(C)O)C(C)C)CC1=CC=CC=C1 XVVOERDUTLJJHN-UHFFFAOYSA-N 0.000 description 1
- 108090000445 Parathyroid hormone Proteins 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 229940123464 Thiazolidinedione Drugs 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229960001519 exenatide Drugs 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 108010036598 gastric inhibitory polypeptide receptor Proteins 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 108010004367 lixisenatide Proteins 0.000 description 1
- 229960001093 lixisenatide Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005447 octyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 108010048573 taspoglutide Proteins 0.000 description 1
- WRGVLTAWMNZWGT-VQSPYGJZSA-N taspoglutide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NC(C)(C)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)C(C)(C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 WRGVLTAWMNZWGT-VQSPYGJZSA-N 0.000 description 1
- 229950007151 taspoglutide Drugs 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161491446P | 2011-05-31 | 2011-05-31 | |
| US61/491,446 | 2011-05-31 | ||
| US201161535750P | 2011-09-16 | 2011-09-16 | |
| US61/535,750 | 2011-09-16 | ||
| US201161569759P | 2011-12-12 | 2011-12-12 | |
| US61/569,759 | 2011-12-12 | ||
| PCT/US2012/040250 WO2012166951A1 (en) | 2011-05-31 | 2012-05-31 | Novel glp-1 receptor stabilizers and modulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016061862A Division JP2016128509A (ja) | 2011-05-31 | 2016-03-25 | 新規ｇｌｐ−１受容体安定剤および調節剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014527027A JP2014527027A (ja) | 2014-10-09 |
| JP2014527027A5 true JP2014527027A5 (cg-RX-API-DMAC7.html) | 2016-05-19 |
| JP6007417B2 JP6007417B2 (ja) | 2016-10-12 |
Family
ID=47259864
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513706A Expired - Fee Related JP6007417B2 (ja) | 2011-05-31 | 2012-05-31 | 新規ｇｌｐ−１受容体安定剤および調節剤 |
| JP2016061862A Pending JP2016128509A (ja) | 2011-05-31 | 2016-03-25 | 新規ｇｌｐ−１受容体安定剤および調節剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016061862A Pending JP2016128509A (ja) | 2011-05-31 | 2016-03-25 | 新規ｇｌｐ−１受容体安定剤および調節剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US9278910B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2713722B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6007417B2 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2713722T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2634716T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2713722T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012166951A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011156655A2 (en) | 2010-06-09 | 2011-12-15 | Receptos, Inc. | Novel glp-1 receptor stabilizers and modulators |
| EP2713722B1 (en) | 2011-05-31 | 2017-03-15 | Receptos, LLC | Novel glp-1 receptor stabilizers and modulators |
| CN104080767A (zh) | 2011-12-12 | 2014-10-01 | 瑞塞普托斯公司 | 新的glp-1受体调节剂 |
| KR20150008406A (ko) | 2012-05-15 | 2015-01-22 | 노파르티스 아게 | Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체 |
| EA026559B1 (ru) | 2012-05-15 | 2017-04-28 | Новартис Аг | Соединения и композиции для ингибирования активности abl1, abl2 и bcr-abl1 |
| CN104379574B (zh) | 2012-05-15 | 2017-03-01 | 诺华股份有限公司 | 用于抑制abl1、abl2和bcr‑abl1的活性的苯甲酰胺衍生物 |
| HRP20180695T1 (hr) | 2012-05-15 | 2018-06-01 | Novartis Ag | Derivati benzamida za inhibiranje aktivnosti od abl1, abl2 i bcr-abl1 |
| WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
| HK1222176A1 (zh) | 2013-06-11 | 2017-06-23 | Receptos Llc | 新型glp-1受体调节剂 |
| DK3054936T5 (da) | 2013-10-10 | 2024-03-18 | Eastern Virginia Medical School | 4-((2-hydroxy-3-methoxybenzyl)amino) benzensulfonamid derivater som 12-lipoxygenase inhibitorer |
| WO2016015014A1 (en) | 2014-07-25 | 2016-01-28 | Receptos, Inc. | Novel glp-1 receptor modulators |
| EP3174868B1 (en) | 2014-08-01 | 2021-08-25 | Nuevolution A/S | Compounds active towards bromodomains |
| RU2017107558A (ru) | 2014-09-15 | 2018-10-18 | Руджен Холдингс (Кайман) Лимитед | Производные пирролопиримидина в качестве антагонистов nmda-рецептора nr2b |
| KR102497644B1 (ko) | 2014-12-10 | 2023-02-08 | 리셉토스 엘엘씨 | Glp-1 수용체 조절제 |
| WO2016126869A1 (en) | 2015-02-04 | 2016-08-11 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists |
| MX380424B (es) | 2015-06-01 | 2025-03-12 | Rugen Holdings Cayman Ltd | Compuestos heterociclicos de 3,3-difluorpiperidina carbamato como antagonistas del receptor de n-metil-d-aspartato (nmda) nr2b. |
| EP3101007A1 (en) * | 2015-06-05 | 2016-12-07 | Lead Pharma Cel Models IP B.V. | Ror gamma (rory) modulators |
| EP3310767B1 (en) | 2015-06-22 | 2020-07-22 | Actelion Pharmaceuticals Ltd. | 2,5-disubstituted benzoxazole and benzothiazole compounds as nadph oxidase 4 inhibitors |
| US20180194769A1 (en) | 2015-07-06 | 2018-07-12 | Rodin Therapeutics, Inc. | Hetero-halo inhibitors of histone deacetylase |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| SI3356358T1 (sl) * | 2015-10-02 | 2020-09-30 | Syngenta Participations Ag | Mikrobiocidni derivati oksadiazola |
| TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| CA3005727A1 (en) | 2015-11-19 | 2017-05-26 | Incyte Corporation | Substituted 2-methylbiphenyl-3-yl heterocyclic compounds and pharmaceutical compositions thereof useful as immunomodulators |
| CR20180374A (es) | 2015-12-22 | 2018-10-16 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| JP6943857B2 (ja) | 2015-12-22 | 2021-10-06 | シンジェンタ パーティシペーションズ アーゲー | 有害生物防除活性ピラゾール誘導体 |
| MA44860A (fr) | 2016-05-06 | 2019-03-13 | Incyte Holdings Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3028685A1 (en) | 2016-06-20 | 2017-12-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018013789A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US11000526B2 (en) | 2016-11-22 | 2021-05-11 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| JP7120549B2 (ja) * | 2016-12-15 | 2022-08-17 | 小野薬品工業株式会社 | Ｔｒｅｋ（ｔｗｉｋ関連ｋチャネル）チャネルのアクチベータ |
| JP7303108B2 (ja) | 2016-12-22 | 2023-07-04 | インサイト・コーポレイション | 免疫調節剤としての二環式複素芳香環化合物 |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CR20190318A (es) | 2016-12-22 | 2019-10-21 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| SG10202106743QA (en) | 2016-12-22 | 2021-08-30 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| HUE057849T2 (hu) | 2017-01-11 | 2022-06-28 | Alkermes Inc | Hiszton deacetiláz biciklusos gátlói |
| EP3601216B1 (en) | 2017-03-21 | 2023-10-25 | Arbutus Biopharma Corporation | Substituted dihydroindene-4-carboxamides and analogs thereof, and methods using same for the treatment of hepatitis b virus infection |
| EP3615524B1 (en) | 2017-04-28 | 2022-11-09 | Receptos Llc | Novel glp-1 receptor modulators |
| ES3008911T3 (en) | 2017-07-11 | 2025-03-25 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| HUE058799T2 (hu) | 2017-08-07 | 2022-09-28 | Alkermes Inc | Hiszton-deacetiláz biciklusos inhibitorai |
| KR102717600B1 (ko) | 2017-10-06 | 2024-10-15 | 포르마 세라퓨틱스 인크. | 유비퀴틴 특이적 펩티다제 30의 억제 |
| EP4212529B1 (en) | 2018-03-30 | 2025-01-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP4520328A3 (en) | 2018-05-11 | 2025-04-16 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CA3098628A1 (en) | 2018-05-17 | 2019-11-21 | Forma Therapeutics, Inc. | Fused bicyclic compounds useful as ubiquitin-specific peptidase 30 inhibitors |
| PT3860989T (pt) | 2018-10-05 | 2023-06-30 | Forma Therapeutics Inc | Pirrolinas fundidas que atuam como inibidores da protease 30 específica da ubiquitina (usp30) |
| AU2019387370A1 (en) | 2018-11-30 | 2021-06-10 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| CR20220190A (es) | 2019-09-30 | 2022-06-15 | Incyte Corp | Compuestos de pirido [3,2-d] primidina como inmunomoduladores |
| EP4058461A1 (en) | 2019-11-11 | 2022-09-21 | Incyte Corporation | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| CN112812077B (zh) * | 2019-11-18 | 2023-08-22 | 中国科学院上海药物研究所 | 苯甲酰胺类化合物及其制备方法、药物组合物和用途 |
| SI4069691T1 (sl) | 2019-12-06 | 2025-02-28 | Vertex Pharmaceuticals Incorporated | Substituirani tetrahidrofurani kot modulatorji natrijevih kanalčkov |
| CA3171979A1 (en) | 2020-03-27 | 2021-09-30 | Josep Bassaganya-Riera | Plxdc2 ligands |
| KR102576148B1 (ko) * | 2020-04-13 | 2023-09-07 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| US11760756B2 (en) | 2020-11-06 | 2023-09-19 | Incyte Corporation | Crystalline form of a PD-1/PD-L1 inhibitor |
| PE20231438A1 (es) | 2020-11-06 | 2023-09-14 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo |
| EP4347031B1 (en) | 2021-06-04 | 2025-10-29 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| CN120903919B (zh) * | 2025-10-11 | 2025-12-23 | 河北鼎瓷电子科技股份有限公司 | 绝缘氧化铝多层陶瓷基板及其制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1062206B (it) | 1974-02-01 | 1983-09-20 | Rotta Research Lab S P A A S | Derivati della tirosina attivi sulla muscolatura liscia |
| DE2423536A1 (de) | 1974-05-15 | 1975-11-27 | Bayer Ag | 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| CA2277112C (en) | 1997-01-07 | 2008-08-26 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
| US6583139B1 (en) | 1997-07-31 | 2003-06-24 | Eugene D. Thorsett | Compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| PL338457A1 (en) | 1997-07-31 | 2000-11-06 | Elan Pharm Inc | Sulphonylated dipeptidic compounds capable to inhibit adhesion of leucocytes through the mediation of vla-4 |
| TR200000482T2 (tr) | 1997-08-22 | 2000-06-21 | F. Hoffmann-La Roche Ag. | N-Aroilfenilalanin türevleri. |
| US6191171B1 (en) * | 1997-11-20 | 2001-02-20 | Merck & Co., Inc. | Para-aminomethylaryl carboxamide derivatives |
| BR9916027A (pt) | 1998-12-07 | 2001-08-28 | Sod Conseils Rech Applic | Análogos de glp-1 |
| EP1609478A1 (en) | 1999-01-14 | 2005-12-28 | Amylin Pharmaceuticals, Inc. | Exendin agonist peptide formulations |
| TW200528436A (en) | 1999-09-22 | 2005-09-01 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| DK1263745T3 (da) | 2000-03-07 | 2004-08-16 | Aventis Pharma Gmbh | Substituerede 3-phenyl-5-alkoxy-1,3,4-oxadiaxol-2-oner og anvendelse deraf til inhibering af hormonfölsom lipase |
| AU2002350217A1 (en) * | 2001-12-04 | 2003-06-17 | Bristol-Myers Squibb Company | Glycinamides as factor xa inhibitors |
| ATE464299T1 (de) | 2002-02-20 | 2010-04-15 | Ajinomoto Kk | Neues phenylalaninderivat |
| US20070276034A1 (en) * | 2002-05-31 | 2007-11-29 | Luke Esposito | Compounds, compositions and methods for the treatment of synucleinopathies |
| CA2497440C (en) | 2002-09-04 | 2011-03-22 | Schering Corporation | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
| RU2380369C9 (ru) * | 2002-09-04 | 2011-07-10 | Шеринг Корпорейшн | Новые пиразолопиримидины как ингибиторы циклин-зависимой киназы |
| US20040152750A1 (en) * | 2002-12-20 | 2004-08-05 | Kodra Janos Tibor | Novel glucagon antagonists |
| GEP20084477B (en) | 2003-06-13 | 2008-09-10 | S A L V A T Lab Sa | NEW BENZAMIDES AS PPARγ MODULATORS |
| RU2390520C2 (ru) | 2003-12-22 | 2010-05-27 | Адзиномото Ко., Инк. | Новые производные фенилаланина |
| CN1938283A (zh) | 2004-02-10 | 2007-03-28 | 詹森药业有限公司 | 作为α4整联蛋白拮抗剂的哒嗪酮 |
| WO2006117743A1 (en) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Substituted aromatic compounds as antidiabetic agents |
| EP1899304A1 (en) | 2005-05-23 | 2008-03-19 | Arena Pharmaceuticals, Inc. | 5-amino-1h-pyrazole-3-carboxylic acid derivatives as agonists for the g-protein coupled receptor (gpcr) rup38 for the treatment of metabolic-related disorders thereof |
| US7825139B2 (en) * | 2005-05-25 | 2010-11-02 | Forest Laboratories Holdings Limited (BM) | Compounds and methods for selective inhibition of dipeptidyl peptidase-IV |
| EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
| US7816324B2 (en) | 2007-03-13 | 2010-10-19 | Board Of Regents, The University Of Texas System | Composition and method for the treatment of diseases affected by a peptide receptor |
| CA2688136A1 (en) | 2007-06-08 | 2008-12-11 | Advinus Therapeutics Private Limited | Pyrrole-2-carboxamide derivatives as glucokinase activators, their process and pharmaceutical application |
| JP2010148234A (ja) | 2008-12-18 | 2010-07-01 | Seiko Epson Corp | 残留電荷放電回路および電源用半導体装置 |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| WO2011156655A2 (en) | 2010-06-09 | 2011-12-15 | Receptos, Inc. | Novel glp-1 receptor stabilizers and modulators |
| EP2713722B1 (en) | 2011-05-31 | 2017-03-15 | Receptos, LLC | Novel glp-1 receptor stabilizers and modulators |
| CN104080767A (zh) | 2011-12-12 | 2014-10-01 | 瑞塞普托斯公司 | 新的glp-1受体调节剂 |
| HK1222176A1 (zh) | 2013-06-11 | 2017-06-23 | Receptos Llc | 新型glp-1受体调节剂 |
| WO2016015014A1 (en) | 2014-07-25 | 2016-01-28 | Receptos, Inc. | Novel glp-1 receptor modulators |
-
2012
- 2012-05-31 EP EP12793320.8A patent/EP2713722B1/en active Active
- 2012-05-31 ES ES12793320.8T patent/ES2634716T3/es active Active
- 2012-05-31 WO PCT/US2012/040250 patent/WO2012166951A1/en not_active Ceased
- 2012-05-31 JP JP2014513706A patent/JP6007417B2/ja not_active Expired - Fee Related
- 2012-05-31 US US14/122,176 patent/US9278910B2/en not_active Expired - Fee Related
- 2012-05-31 PT PT127933208T patent/PT2713722T/pt unknown
- 2012-05-31 DK DK12793320.8T patent/DK2713722T3/en active
-
2016
- 2016-01-15 US US14/997,364 patent/US9700543B2/en active Active
- 2016-03-25 JP JP2016061862A patent/JP2016128509A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014527027A5 (cg-RX-API-DMAC7.html) | ||
| JP2016528180A5 (cg-RX-API-DMAC7.html) | ||
| JP2015505842A5 (cg-RX-API-DMAC7.html) | ||
| US10035819B2 (en) | PPAR agonists and methods of use thereof | |
| KR101245062B1 (ko) | 칼슘이온-방출-활성화-칼슘이온 채널을 조절하는 방법 | |
| KR20170123658A (ko) | 장 수용체를 활성화시키는 파네소이드 x 수용체 작용제를 사용한 성인 잠복성 자가면역 당뇨병의 치료 | |
| CN109790135B (zh) | 用于治疗或预防与痛风或高尿酸血症相关的症状的化合物、组合物和方法 | |
| JP2006500325A (ja) | 新規なグルカゴンアンタゴニスト | |
| JP2019031560A5 (cg-RX-API-DMAC7.html) | ||
| JP2010513283A5 (cg-RX-API-DMAC7.html) | ||
| WO2014181287A1 (en) | Heterocyclyl compounds and uses thereof | |
| WO2014165827A1 (en) | Ppar agonists | |
| HK1202119A1 (en) | Novel glp-1 receptor modulators | |
| AU2005286701A1 (en) | Compounds for inflammation and immune-related uses | |
| CA2646962A1 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| JP2016505619A5 (cg-RX-API-DMAC7.html) | ||
| JP2017526734A5 (cg-RX-API-DMAC7.html) | ||
| HRP20190668T1 (hr) | Tetrazolonom supstituirani dihidropiridinonski mgat2 inhibitori | |
| RU2018120242A (ru) | Хинолиновые соединения, способы их получения и их применения в качестве лекарственного средства, ингибирующего транспортер уратов | |
| JP2017508795A5 (cg-RX-API-DMAC7.html) | ||
| JP2019535792A (ja) | インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| US20090136472A1 (en) | Use of thiazole derivatives and analogues in disorders caused by free fatty acids | |
| JP2009528997A5 (cg-RX-API-DMAC7.html) | ||
| JP2008530242A5 (cg-RX-API-DMAC7.html) | ||
| JP2020505412A (ja) | Ｒｏｒガンマモジュレーター及びその使用 |